email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1456 - 1470
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Apollomics Acquires Immunotherapy for Gastrointestinal Cancers
$5.00
Available
Apollomics Acquires Rights to Novel Iterion Oncology Candidate
$5.00
Available
Ascletis Participates in $80 Million Funding of US Partner, Sagimet
$5.00
Available
Hengrui Acquires PI3k? Inhibitor Rights from Shanghai Lingli Pharma
$5.00
Available
I-Mab Approved to Start China Trial of Complement Factor Inhibitor
$5.00
Available
Adagene Completes $140 Million US IPO, Climbs 56% Higher
$5.00
Available
Nuance Acquires China Rights to Osteoarthritis Pain Drug in $100 Million Deal
$5.00
Available
Wuhan's Neurophth Raises $62 Million for AAV-delivered Gene Therapies
$5.00
Available
Apollomics of Hangzhou Acquires Global (ex-China) Rights to Novel Cancer Candidate
$5.00
Available
China Medical System Acquires Luqa Ventures, a China Dermatology Company
$5.00
Available
Beijing InnoCare to Start Phase III Combination Trial of BTK Inhibitor
$5.00
Available
I-Mab Starts China and US Trials of CD73 Immunotherapy
$5.00
Available
Beijing InnoCare Raises $407 Million in Private Placements with Hillhouse and Vivo
$5.00
Available
Beijing neoX Biotech Closes $30 Million A Round for AI Drug Discovery
$5.00
Available
Adagene Licenses its mAb Masking Technology to Exelixis in Collaboration
$5.00
Available